Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated

Core Viewpoint - Robbins LLP has filed a class action on behalf of investors who purchased Corcept Therapeutics Incorporated (CORT) common stock between October 31, 2024, and December 30, 2025, alleging that the company misled investors regarding the viability of its new product candidate, relacorilant [1][2]. Company Overview - Corcept Therapeutics is a pharmaceutical company focused on developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol effects [1]. Allegations - The class action alleges that Corcept misrepresented the clinical trials supporting relacorilant as a treatment for hypercortisolism, claiming they provided "powerful support" for the New Drug Application (NDA) submitted to the FDA [2]. - Defendants stated they had communicated with the FDA and were confident in the NDA submission, foreseeing no impediments to approval, while the FDA had raised concerns about the adequacy of clinical evidence [2]. Impact of FDA Response - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the NDA of relacorilant, stating that additional evidence of effectiveness was required [3]. - Following this announcement, Corcept's stock price fell from $70.20 on December 30, 2025, to $34.80 on December 31, 2025, representing a decline of 50.4% [3]. Shareholder Actions - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4].